Rain Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Rain Oncology

10/11/2021 22:02

* Rain Therapeutics Inc  RAIN.OQ  reported a quarterly adjusted
loss of 70 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 48 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Rain Therapeutics Inc's reported EPS for the quarter was a
loss of 70 cents​.
* The mean earnings estimate of analysts had risen by
about 10.1% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Rain Therapeutics Inc shares had risen by 13.6% this quarter.
* The company reported a quarterly loss of $18.43 million.
* Wall Street's median 12-month price target for Rain
Therapeutics Inc is $25.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 10 at 10:02 p.m.
 ​All figures in US dollars unless otherwise stated